An Open-label, Randomized, Two-period, Two-sequence Crossover Trial to Assess the Bioequivalence of the Liquid Formulation Versus the Freeze-dried Formulation of 900 IU r-hFSH and 450 IU r-hLH in Pergoveris, Administered Subcutaneously in Pituitary Suppressed Healthy Premenopausal Female Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Follitropin alfa/lutropin alfa (Primary)
- Indications Female infertility
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 07 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.
- 12 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Oct 2015, according to ClinicalTrials.gov record.